alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsNASA Workshop on Computational Structural Mechanics 1987, part 2Advanced methods and testbed/simulator development  topics are discussed. Computational Structural Mechanics (CSM) testbed architecture, engine structures simulation, applications to laminate structures, and a generic element processor are among the topics covered.Document ID19890020418Acquisition SourceLegacy CDMSDocument TypeConference ProceedingsAuthorsSykes, Nancy P.*(Analytical Services and Materials, Inc., Hampton VA., United States)*Date AcquiredSeptember 6, 2013Publication DateFebruary 1, 1989Subject CategoryStructural MechanicsReport/Patent NumberNAS 1.55:10012-PT-2NASA-CP-10012-PT-2Accession Number89N29789Funding Number(s)PROJECT: RTOP 505-63-01-10Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType19890020418.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsIDRelationTitleN89-29790 through N89-29798Workvisibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
#### § 357.180 Professional labeling.

The labeling provided to health professionals (but not to the general public) may contain an additional indication: “For the treatment of common roundworm infestation.”
#### § 226.10 Personnel.

The key personnel and any consultants involved in the manufacture and control of the Type A medicated article(s) shall have a background of appropriate education or appropriate experience or combination thereof for assuming responsibility to assure that the Type A medicated article(s) has the proper labeling and the safety, identity, strength, quality, and purity that it purports to possess.
# L_2019188EN.01013101.xml

| 12.7.2019 | EN | Official Journal of the European Union | L 188/131 |
| --- | --- | --- | --- |

12.7.2019

EN

Official Journal of the European Union

L 188/131

---

Joint statement of the European Parliament, the Council and the Commission

The European Parliament, the Council and the Commission note that the process for selecting the location of the seat of the European Labour Authority (ELA) was not concluded at the time of the adoption of its founding Regulation (1).

1

Recalling the commitment to sincere and transparent cooperation and recalling the Treaties, the three Institutions acknowledge the value of exchange of information from the initial stages of the process for the selection of the seat of the ELA.

Such early exchange of information would make it easier for the three Institutions to exercise their rights according to the Treaties through the related procedures.

The European Parliament and the Council take note of the Commission's intention to take any appropriate steps in order for the founding Regulation to provide for a provision on the location of the seat of the ELA, and to ensure that the ELA operates autonomously in line with that Regulation.

---

(1)  
  OJ L 186, 11.7.2019, p. 21.

1

---
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-1996
<PERIOD-START>                             APR-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                           2,050
<SECURITIES>                                     4,672
<RECEIVABLES>                                    6,538
<ALLOWANCES>                                      (30)
<INVENTORY>                                      3,679
<CURRENT-ASSETS>                                16,951
<PP&E>                                           4,505
<DEPRECIATION>                                 (4,373)
<TOTAL-ASSETS>                                  19,130
<CURRENT-LIABILITIES>                            4,097
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        24,990
<OTHER-SE>                                     (9,907)
<TOTAL-LIABILITY-AND-EQUITY>                    19,130
<SALES>                                         14,802
<TOTAL-REVENUES>                                14,802
<CGS>                                            8,089
<TOTAL-COSTS>                                   14,096
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                    986
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                986
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       986
<EPS-PRIMARY>                                      .09
<EPS-DILUTED>                                      .09
        

</TABLE>
###### Editorial Note on Part 172

#### Editorial Note:

Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 172.710 Adjuvants for pesticide use dilutions.

The following surfactants and related adjuvants may be safely added to pesticide use dilutions by a grower or applicant prior to application to the growing crop:

*n-*Alkyl (C8-C18) amine acetate, where the alkyl groups (C8-C18) are derived from coconut oil, as a surfactant in emulsifier blends at levels not in excess of 5 percent by weight of the emulsifier blends that are added to herbicides for application to corn and sorghum.

Di*-n-*alkyl (C8-C18) dimethyl ammonium chloride, where the alkyl groups (C8-C18) are derived from coconut oil, as surfactants in emulsifier blends at levels not in excess of 5 percent by weight of emulsifier blends that are added to herbicides for application to corn or sorghum.

Diethanolamide condensate based on a mixture of saturated and unsaturated soybean oil fatty acids (C16-C18) as a surfactant in emulsifier blends that are added to the herbicide atrazine for application to corn.

Diethanolamide condensate based on stripped coconut fatty acids (C10 C18) as a surfactant in emulsifier blends that are added to the herbicide atrazine for application to corn.

α-(*p-*Dodecylphenyl)*-omega-*hydroxypoly (oxyethylene) produced by the condensation of 1 mole of dodecylphenol (dodecyl group is a proplyene tetramer isomer) with an average of 4-14 or 30-70 moles of ethylene oxide; if a blend of products is used, the average number of moles of ethylene oxide reacted to produce any product that is a component of the blend shall be in the range of 4-14 or 30-70.

Ethylene dichloride.

Polyglyceryl phthalate ester of coconut oil fatty acids.

α-[*p-*(1,1,3,3-Tetramethylbutyl) phenyl]*-omega-*hydroxypoly(oxyethylene) produced by the condensation of 1 mole of *p-*(1,1,3,3-tetramethylbutyl) phenol with an average of 4-14 or 30-70 moles of ethylene oxide; if a blend of products is used, the average number of moles of ethylene oxide reacted to produce any product that is a component of the blend shall be in the range of 4-14 or 30-70.

α-[*p-*(1,1,3,3-Tetramethylbutyl) phenyl]-*omega-*hydroxypoly(oxyethylene) produced by the condensation of 1 mole of *p-*(1,1,3,3-tetramethylbutyl) phenol with 1 mole of ethylene oxide.

Sodium acrylate and acrylamide copolymer with a minimum average molecular weight of 10,000,000 in which 30 percent of the polymer is comprised of acrylate units and 70 percent acrylamide units, for use as a drift control agent in herbicide formulations applied to crops at a level not to exceed 0.5 ounces of the additive per acre.
Editorial Note on Part 17
Editorial Note: Nomenclature changes to part 17 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45065, July 14, 2023.

§ 17.3 Definitions. The following definitions are applicable in this part: ( a ) For specific acts giving rise to civil money penalty actions brought under 21 U.S.C. 333(f)(1): ( 1 ) *Significant departure,* for the purpose of interpreting 21 U.S.C. 333(f)(1)(B)(i), means a departure from requirements that is either a single major incident or a series of incidents that collectively are consequential.
( 2 ) *Knowing departure,* for the purposes of interpreting 21 U.S.C. 333(f)(1)(B)(i), means a departure from a requirement taken: ( i ) With actual knowledge that the action is such a departure; or
( ii ) In deliberate ignorance of a requirement; or
( ii ) In reckless disregard of a requirement.
( 3 ) *Minor violations,* for the purposes of interpreting 21 U.S.C. 333(f)(1)(B)(ii), means departures from requirements that do not rise to a level of a single major incident or a series of incidents that are collectively consequential.
( 4 ) *Defective,* for the purposes of interpreting 21 U.S.C. 333(f)(1)(B)(iii), includes any defect in performance, manufacture, construction, components, materials, specifications, design, installation, maintenance, or service of a device, or any defect in mechanical, physical, or chemical properties of a device.
( b ) Person or respondent includes an individual, partnership, corporation, association, scientific or academic establishment, government agency or organizational unit thereof, or other legal entity, or as may be defined in the act or regulation pertinent to the civil penalty action being brought.
( c ) *Presiding officer* means an administrative law judge qualified under 5 U.S.C. 3105.
( d ) Any term that is defined in the act has the same definition for civil money penalty actions that may be brought under that act.
( e ) Any term that is defined in Title 21 of the Code of Federal Regulations has the same definition for civil money penalty actions that may arise from the application of the regulation(s).
( f ) Any term that is defined in the PHS Act has the same definition for civil money penalty actions that may be brought under that act.
( g ) *Departmental Appeals Board (DAB)* means the Departmental Appeals Board of the Department of Health and Human Services.
[60 FR 38626, July 27, 1995, as amended at 82 FR 34402, July 25, 2017]
<PAGE>   1
                                                                   EXHIBIT 23.1


              INDEPENDENT AUDITORS' CONSENT AND REPORT ON SCHEDULE

We consent to the use in the Registration Statement No. 333-23013 of MiniMed
Inc.  on Form S-3 of our report dated January 17, 1997 (February 20, 1997 as to
the last paragraph of note 3) appearing in the Prospectus, which is a part of
that Registration Statement, to the reference to us under the headings
"Selected Consolidated Financial Data" and "Experts" in such Prospectus, and
the incorporation by reference of our report dated January 17, 1997 (February
20, 1997 as to the last paragraph of note 3) appearing in this annual report on
Form 10-K of MiniMed Inc. for the year ended December 27, 1996.

Our audits of the financial statements referred to in our aforementioned report
also included the financial statements schedule of MiniMed Inc., listed in Item
14.  This financial statement schedule is the responsibility of the Company's
management.  Our responsibility is to express an opinion based on our audits.
In our opinion, such financial statement schedule, when considered in relation
to the basic financial statements taken as a whole, presents fairly in all
material aspects the information set forth therein.


/s/ Deloitte & Touche LLP

Los Angeles, California
March 21, 1997
Editorial Note on Part 369
Editorial Note: Nomenclature changes to part 369 appear at 69 FR 13717, Mar. 24, 2004.

§ 369.2 Definitions. ( a ) As used in this part, the term *act* means the Federal Food, Drug, and Cosmetic Act.
( b ) The terms *drugs* and *devices* are defined in section 201(g) and (k) of the act.
( c ) Official compendia are defined in section 201(j) of the act.
#### § 26.15 Monitoring continued equivalence.

Monitoring activities for the purpose of maintaining equivalence shall include review of the exchange of inspection reports and their quality and timeliness; performance of a limited number of joint inspections; and the conduct of common training sessions.
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.145 Guidance documents. ( a ) FDA has made available guidance documents under § 10.115 of this chapter to help you to comply with certain requirements of this part.
( b ) The Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) maintain lists of guidance documents that apply to the centers' regulations. The lists are maintained on the Internet and are published annually in the Federal Register. A request for a copy of the CDER list should be directed to the Office of Training and Communications, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002. A request for a copy of the CBER list should be directed to the Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Communication, Outreach and Development, 10903 New Hampshire Ave., Bldg. 71, Rm. 3103, Silver Spring, MD 20993-0002.
[65 FR 56479, Sept. 19, 2000, as amended at 74 FR 13113, Mar. 26, 2009; 80 FR 18091, Apr. 3, 2015]
Exhibit 31.2  CERTIFICATION  I, Anders A. Suarez, certify that:  1. I have reviewed this annual report on Form 10-K of Amerityre Corporation;  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;  4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others, particularly during the period in which this report is being prepared; and  (b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and  (c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.  5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.  Date: September 12, 2008  /s/Anders A. Suarez
Anders A. Suarez
Chief Financial Officer
----

|   | (1) | In connection with the Annual Report of the Company on form 10-K for the twelve month period ended May 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) and Section 15(d) of the Securities and Exchange Act of 1934; and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company for the periods presented therein.. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | By:                      | /s/ Daniel W. Dowe          |
|--------|--------------------------|-----------------------------|
|   |                     | Daniel W. Dowe              |
|   |                     | Chief Executive Officer and |
|   |                     | Chief Financial Officer     |
|   |                     |                        |
|   | Date: September 14, 2009 |

----
##### 



EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley
Act of 2002, I, Gordon L. Ellis, President and Chief Executive Officer, certify
that:

1.     I have read this quarterly report on Form 10-QSB of International
Absorbents, Inc.;

2.     To my knowledge, this report fully complies with the requirements of
section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

3.     To my knowledge, the information in this report fairly presents, in all
material respects, the financial condition and results of operations as of
October 31, 2003.

Date: December 10, 2003



| | /s/ Gordon L. Ellis
Gordon L. Ellis, President and Chief Executive Officer
| | --------------------------------------------------------------------------

Assigned original of this written statement required by section 906 has been
provided to International Absorbents Inc. and will be retained by International
Absorbents Inc. and furnished to the Securities and Exchange Commission or its
staff upon request. This certification is accompanying the Form 10-QSB solely
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being
filed as part of the Form 10-QSB or as a separate disclosure document.

26
Exhibit 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of LMIC, Inc. (the "Company") on Form
10-KSB for the period ending December 31, 2003 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), Kwok Leung Li, Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.



By: /s/ Kwok Leung Li
-----------------------
Kwok Leung Li
Chief Executive Officer
October 18, 2004
Editorial Note on Part 314
Editorial Note: Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

§ 314.72 Change in ownership of an application. ( a ) An applicant may transfer ownership of its application. At the time of transfer the new and former owners are required to submit information to the Food and Drug Administration as follows: ( 1 ) The former owner shall submit a letter or other document that states that all rights to the application have been transferred to the new owner.
( 2 ) The new owner shall submit an application form signed by the new owner and a letter or other document containing the following: ( i ) The new owner's commitment to agreements, promises, and conditions made by the former owner and contained in the application;
( ii ) The date that the change in ownership is effective; and
( iii ) Either a statement that the new owner has a complete copy of the approved application, including supplements and records that are required to be kept under § 314.81, or a request for a copy of the application from FDA's files. FDA will provide a copy of the application to the new owner under the fee schedule in § 20.45 of FDA's public information regulations.
( b ) The new owner shall advise FDA about any change in the conditions in the approved application under § 314.70, except the new owner may advise FDA in the next annual report about a change in the drug product's label or labeling to change the product's brand or the name of its manufacturer, packer, or distributor.
[50 FR 7493, Feb. 22, 1985; 50 FR 14212, Apr. 11, 1985, as amended at 50 FR 21238, May 23, 1985; 67 FR 9586, Mar. 4, 2002; 68 FR 25287, May 12, 2003]